Apyx Medical Corp (NASDAQ:APYX)’s share price was up 8.3% during trading on Wednesday . The company traded as high as $7.99 and last traded at $7.94, approximately 122,176 shares changed hands during trading. A decline of 43% from the average daily volume of 214,307 shares. The stock had previously closed at $7.33.
A number of equities analysts recently commented on APYX shares. Zacks Investment Research raised Apyx Medical from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research note on Thursday, November 14th. Piper Jaffray Companies increased their price target on Apyx Medical to $10.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, ValuEngine raised Apyx Medical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $8.94.
The firm has a market capitalization of $272.66 million, a P/E ratio of -27.38 and a beta of 0.16. The firm has a 50 day moving average price of $7.06 and a 200-day moving average price of $6.92. The company has a current ratio of 8.73, a quick ratio of 7.93 and a debt-to-equity ratio of 0.01.
Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings data on Monday, November 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. The business had revenue of $7.58 million during the quarter, compared to analyst estimates of $6.78 million. Apyx Medical had a negative return on equity of 20.25% and a negative net margin of 66.77%. The firm’s revenue was up 106.3% compared to the same quarter last year. Research analysts anticipate that Apyx Medical Corp will post -0.6 earnings per share for the current year.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Apyx Medical by 372.5% in the 2nd quarter. BlackRock Inc. now owns 2,123,214 shares of the company’s stock valued at $14,268,000 after purchasing an additional 1,673,854 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Apyx Medical by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,366,256 shares of the company’s stock valued at $9,181,000 after purchasing an additional 35,899 shares during the last quarter. State Street Corp lifted its stake in shares of Apyx Medical by 34.2% in the 3rd quarter. State Street Corp now owns 557,677 shares of the company’s stock valued at $3,775,000 after purchasing an additional 142,098 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Apyx Medical by 55.8% in the 2nd quarter. Northern Trust Corp now owns 158,309 shares of the company’s stock valued at $1,064,000 after purchasing an additional 56,694 shares during the last quarter. Finally, P.A.W. Capital Corp bought a new stake in shares of Apyx Medical in the 2nd quarter valued at approximately $806,000. 54.20% of the stock is owned by institutional investors and hedge funds.
About Apyx Medical (NASDAQ:APYX)
Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.
Further Reading: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.